

Press release

Lund, May 21, 2021

EQL Pharma AB (publ)
556713-3425

EQL PHARMA

Mellozzan (melatonin) is now Reimbursed

The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has today decided that Mellozzan (melatonin) tablets 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg should be included in the pharmaceutical benefit (reimbursement) system with a limitation to the indication "Insomnia in children and adolescents 6 - 17 years with ADHD where sleep hygiene measures have been insufficient".

5-7% of children and young people in Sweden have ADHD according to the National Board of Health and Welfare, and the incidence of children with sleep difficulties (insomnia) is very high, up to 80%, among these. The result is a vicious circle where lack of sleep aggravates ADHD symptoms during the day, which in turn negatively affects sleep at night. Not only the child, but also parents and other family members experience a reduced quality of life due to this, studies show", says Christer Fåhraeus, CEO of EQL Pharma. "Melatonin, which is the active substance in Mellozzan, is also a body-specific hormone and is today classified as the only permitted pharmaceutical for these children. But it is important that they do not take a larger dose than necessary, which is why we offer 6 different strengths. "

For further information, please contact:
Christer Fåhraeus

CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.